China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision medicine biotech Nested Therapeutics, Inc. Under the agreement, HitGen will leverage its DNA-encoded library (DEL) technology platform to identify hits against targets of interest for Nested. This collaboration combines HitGen’s expertise in DEL technology with Nested’s focus on precision medicine, aiming to advance drug discovery and development.
HitGen’s DEL Technology and Drug Discovery
HitGen is a global leader in the development and application of DEL technology for early-stage small molecule drug discovery. The company’s platform encompasses over 1.2 trillion small molecules generated through DEL technology, and the efficiency of the screening process has enabled HitGen to support drug discovery projects for numerous organizations globally.
Nested Therapeutics’ Precision Medicine Approach
Nested Therapeutics is a biotechnology company dedicated to discovering and developing novel, targeted small molecule therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and employs a platform that integrates genomics, computational chemistry, proteomics, and AI to target untapped mutations. Nested’s mission is to improve outcomes for millions of patients by harnessing the potential of these mutations.-Fineline Info & Tech